<List><item><source>MED</source><extId>26157747</extId><pmcid>PMC4493353</pmcid><annotations><annotation><prefix>Phase I trial (</prefix><exact>NCT01853618</exact><postfix>) for tremelimumab (CTLA-</postfix><tags><tag><name>NCT01853618</name><uri>http://identifiers.org/clinicaltrials/NCT01853618</uri></tag></tags><id>http://europepmc.org/articles/PMC4493353#europepmc-038f3caa0f28851d7eb4103737c75feb</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>nd phase I/2 trial (</prefix><exact>NCT01658878</exact><postfix>) for nivolumab (pro</postfix><tags><tag><name>NCT01658878</name><uri>http://identifiers.org/clinicaltrials/NCT01658878</uri></tag></tags><id>http://europepmc.org/articles/PMC4493353#europepmc-c267bceaadb330bdd50268cfed3881b8</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation></annotations></item></List>